Subject(s)
Carcinoma, Non-Small-Cell Lung/diagnosis , Carcinoma, Non-Small-Cell Lung/therapy , Carcinoma, Small Cell/diagnosis , Carcinoma, Small Cell/therapy , Cooperative Behavior , Interdisciplinary Communication , Lung Neoplasms/diagnosis , Lung Neoplasms/therapy , Pancoast Syndrome/diagnosis , Pancoast Syndrome/therapy , Carcinoma, Non-Small-Cell Lung/pathology , Carcinoma, Non-Small-Cell Lung/prevention & control , Carcinoma, Small Cell/pathology , Carcinoma, Small Cell/prevention & control , Combined Modality Therapy , Early Diagnosis , Follow-Up Studies , Germany , Humans , Lung Neoplasms/pathology , Lung Neoplasms/prevention & control , Neoplasm Staging , Pancoast Syndrome/pathology , Pancoast Syndrome/prevention & control , Societies, MedicalABSTRACT
Two randomized trials, in 1994, have demonstrated the benefit of neoadjuvant chemotherapy, in term of median survival, for stage III lung cancer. Further studies have evaluated the potential benefit of chemotherapy or chemotherapy-radiotherapy association, either for patients suitable for surgery, or for non resectables tumors. However, these treatments treatments may increase the morbidity of surgery. Such an increase has not been demonstrated, except in one study, after chemotherapy alone before surgery. When radiation therapy is associated with pre-operative chemotherapy, the risk of complications seems to be dose dependent: low for doses below 50 Gy, important for doses over 55 Gy. These datas justify pre-operative lung function measurements and modifications of the surgical technic, especially for the lymphadenectomy extension. Despite this potential increase of morbidity, the benefit of neoadjuvant treatment is real.
